AGC Biologics Expands Cell Therapy Development Operations to Asia
AGC Biologics will launch cell therapy process development and clinical manufacturing services in Asia starting July 1, 2025, at AGC Inc.’s Yokohama Technical Center.
This expansion establishes AGC Biologics’ cell therapy manufacturing footprint across three continents, enabling Asian developers to access advanced local capabilities within a world-class infrastructure. “Now Asian developers can benefit from having a local supply within one of the best global infrastructures on the market for cell therapy,” Luca Alberici, Executive Vice President of Global Cell and Gene Technologies at AGC Biologics.
AGC’s growth reflects Washington state’s commitment to supporting globally connected life science leaders driving progress in cell and gene therapies.